Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Jun 24;5(6):e007651.
doi: 10.1136/bmjopen-2015-007651.

Randomised controlled trial of topical kanuka honey for the treatment of rosacea

Irene Braithwaite  1 , Anna Hunt  1 , Judith Riley  1 , James Fingleton  1 , Janwillem Kocks  1 , Andrew Corin  2 , Colin Helm  2 , Davitt Sheahan  3 , Christopher Tofield  4 , Barney Montgomery  5 , Mark Holliday  1 , Mark Weatherall  6 , Richard Beasley  1
Affiliations
Randomized Controlled Trial

Randomised controlled trial of topical kanuka honey for the treatment of rosacea

Irene Braithwaite et al. BMJ Open. .

Abstract

Objective: To investigate the efficacy of topical 90% medical-grade kanuka honey and 10% glycerine (Honevo) as a treatment for rosacea.

Design: Randomised controlled trial with blinded assessment of primary outcome variable.

Setting: Outpatient primary healthcare population from 5 New Zealand sites.

Participants: 138 adults aged ≥ 16, with a diagnosis of rosacea, and a baseline blinded Investigator Global Assessment of Rosacea Severity Score (IGA-RSS) of ≥ 2. 69 participants were randomised to each treatment arm. 1 participant was excluded from the Honevo group, and 7 and 15 participants withdrew from the Honevo and control groups, respectively.

Interventions: Participants were randomly allocated 1:1 to Honevo or control cream (Cetomacrogol), applied twice daily for 8 weeks.

Main outcome measures: The primary outcome measure was the proportion of participants who had a ≥ 2 improvement in the 7-point IGA-RSS at week 8 compared to baseline. Secondary outcomes included change in IGA-RSS and subject-rated visual analogue score of change in severity (VAS-CS) on a 100 mm scale (0 mm 'much worse', 100 mm 'much improved') at weeks 2 and 8.

Results: 24/68 (34.3%) in the Honevo group and 12/69 (17.4%) in the control group had a ≥ 2 improvement in IGA-RSS at week 8 compared to baseline (relative risk 2.03; 95% CI 1.11 to 3.72, p=0.020). The change in IGA-RSS for Honevo compared to control at week 2 minus baseline was -1 (Hodges-Lehman estimate, 95% CI -1 to 0, p=0.03), and at week 8 minus baseline was -1 (Hodges-Lehman estimate, 95% CI -1 to 0, p=0.005). The VAS-CS at week 2 was 9.1 (95% CI 3.5 to 14.7), p=0.002, and at week 8 was 12.3 (95% CI 5.7 to 18.9)¸ p<0.001 for Honevo compared to control.

Conclusions: Honevo is an effective treatment for rosacea.

Trial registration number: This trial was registered in the Australian and New Zealand Clinical Trials Registry ACTRN12614000004662.

Keywords: Kanuka honey; Rosacea; randomised controlled trial.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow of participants through trial.
Figure 2
Figure 2
The difference from baseline in IGA-RSS at week 8 for control and Honevo. Horizontal lines are the 25%, median and 75% quartiles, the symbol is the mean and the whiskers go from maximum to minimum.
See this image and copyright information in PMC

References

    1. Buechner SA. Rosacea: an update. Dermatology 2005;210:100–8. 10.1159/000082564 - DOI - PubMed
    1. Wilkin J, Dahl M, Detmar M et al. . Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2004;50:907–12. 10.1016/j.jaad.2004.01.048 - DOI - PubMed
    1. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol 1989;69:419–23. - PubMed
    1. Powell FC. Clinical practice. Rosacea. N Engl J Med 2005;352:793–803. 10.1056/NEJMcp042829 - DOI - PubMed
    1. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol 2003;139:1444–50. 10.1001/archderm.139.11.1444 - DOI - PubMed

Publication types